Last week, Scandinavian Medical Solutions announced its H1 2024/25 report. As expected from the guidance downgrade back in March, the company has been challenged by hesitant buyers from the uncertain macroeconomic environment. Additionally, an intensified competition has resulted in lower margins.
Due to the market challenges as well as increased capacity costs and investments in its US subsidiary, the company's EBITDA was DKK 0.6m despite a solid topline growth of 20% in H1 2024/25. However, the latest guidance range was maintained with revenue of DKK 200-240m (-12% to +6% revenue growth) and EBITDA of DKK 11-15m for 2024/25, implying that Scandinavian Medical Solutions may be past the most challenging phase in terms of operational profitability.
We have updated our investment case one-pager following the recent news from the H1 2024/25 report. Besides an overview of financials and updated valuation multiples, the investment case one-pager introduces Scandinavian Medical Solutions and highlights key investment reasons and risks.
Earlier today, Scandinavian Medical Solutions' CEO & Partner Jens Hvid Paulsen and Group Commercial Director Patrick Gammelholm Remon presented the company's financial results for H1 2024/25 and the outlook. The presentation was followed by a Q&A session. Watch the full presentation here: https://www.inderes.dk/videos/scandinavian-medical-solutions-praesentation-af-h1-202425
Disclaimer: HC Andersen Capital receives payment from Scandinavian Medical Solutions for a Digital IR subscription agreement. /Kasper Lihn 15:30, 19 May 2025.
This content is only available for logged in users